Nonetheless, we acknowledge that these cases may be subject to selection and confounding biases, and the prolonged survival could partly reflect unusually indolent tumor biology rather than solely the therapeutic effect of KRAS G12C inhibition. The gene discussed is KRAS; the disease is neoplasm.